ENTG:NASDAQEntegris, Inc. Analysis
Data as of 2026-08-01 - not real-time
$119.05
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Entegris is trading at $119.05, well below its 20‑day SMA of $133.15 and 50‑day SMA of $143.34, suggesting short‑term weakness, yet the 200‑day SMA sits at $119.20, providing a long‑term anchor. The RSI of 39.9 points to a near‑oversold condition, while a bearish MACD histogram reinforces downside pressure. However, the forward EPS estimate of $4.70 implies earnings could more than double the trailing $1.76, and analysts have raised price targets to $166–$180, indicating strong growth expectations. The stock’s PE of 67.6 dwarfs the industry average of 32.8 and the DCF fair value of $24.6, flagging a substantial valuation premium. A modest dividend of $0.10 per quarter (0.34% yield) with a 23% payout ratio appears sustainable given positive free cash flow, but the debt‑to‑equity ratio of 92.8% raises leverage concerns. Volatility is extreme at 95% over 30 days and beta exceeds 3, reflecting heightened market sensitivity. Recent news of a dividend authorization and analyst upgrades have sparked a 4.5% price jump on higher‑than‑average volume, but the upcoming Q2 results could add further direction. Overall, the company sits at the intersection of strong secular demand for semiconductor materials and a stretched valuation, making the near‑term outlook mixed while the medium‑term upside remains compelling.
Investors should weigh the upside potential against the high beta, elevated volatility, and leverage. A cautious stance—holding or modest buying on dips—may be prudent until earnings clarity emerges, after which the longer‑term narrative of industry tailwinds could justify a higher allocation.
Investors should weigh the upside potential against the high beta, elevated volatility, and leverage. A cautious stance—holding or modest buying on dips—may be prudent until earnings clarity emerges, after which the longer‑term narrative of industry tailwinds could justify a higher allocation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages and bearish MACD
- Near‑oversold RSI with elevated volatility
- Upcoming Q2 earnings release
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong forward earnings growth and analyst target lifts
- Sustainable dividend and positive free cash flow
- Secular demand for semiconductor materials
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Significant valuation premium versus DCF
- High leverage and beta increasing systematic risk
- Long‑term industry tailwinds in advanced nano‑chip manufacturing
Key Metrics & Analysis
Financial Health
Revenue Growth5.00%
Profit Margin8.18%
P/E Ratio67.6
ROE6.79%
ROA3.75%
Debt/Equity92.80
P/B Ratio4.5
Op. Cash Flow$738.0M
Free Cash Flow$445.1M
Industry P/E32.8
Technical Analysis
TrendNeutral
RSI40.0
Support$106.91
Resistance$155.08
MA 20$133.15
MA 50$143.34
MA 200$119.20
MACDBearish
VolumeStable
Fear & Greed Index92.88
Valuation
Fair Value$24.62
Target Price$166.00
Upside/Downside39.44%
GradeOvervalued
TypeGrowth
Dividend Yield0.34%
Risk Assessment
Beta3.17
Volatility95.11%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.